BLRX Stock Summary and Trading Ideas (Bioline Rx | NASDAQ:BLRX)

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Bioline Rx trades on the NASDAQ stock market under the symbol BLRX.

As of July 27, 2026, BLRX stock price was flat at $2.82 with 4,978 million shares trading.

BLRX has a beta of 1.44, meaning it tends to be more sensitive to market movements. BLRX has a correlation of 0.12 to the broad based SPY ETF.

BLRX has a market cap of $12.26 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioline Rx reported $477,000 in Revenue and $.00 earnings per share. This beat revenue expectation by $134,000 and exceeded earnings estimates by $1.04.

In the last 3 years, BLRX traded as high as $101.20 and as low as $2.15.

BLRX has underperformed the market in the last year with a price return of -37.5% while the SPY ETF gained +17.7%. However, in the short term, BLRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +24.1% vs +3.8% return in SPY. But in the last 2 weeks, BLRX shares have been beat by the market, returning -8.8% compared to an SPY return of -2.1%.

BLRX support price is $2.66 and resistance is $2.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLRX shares will trade within this expected range on the day.